Point of View about Erythropoietin in Treatment of Central Nervous System DiseasesLiu-Zhu Yang1, Rui-Long Li1, Bo Wu2,5, Jin Luo1, Zhong Chen2*, Xin-Ping Yan3and Wei Tan4
- *Corresponding Author:
- Zhong Chen
Department of Orthopedics, Southern Medical University
Zhujiang Hospital, Guangzhou, Guangdong, China
Tel: +86- 15778448908
E-mail: [email protected]
Received date: March 27, 2017; Accepted date: April 12, 2017; Published date: April 19, 2017
Citation: Yang LZ, Li RL, Wu B, Luo J, Chen Z, et al. (2017) Point of View about Erythropoietin in Treatment of Central Nervous System Diseases. J Alzheimers Dis Parkinsonism 7:320. doi:10.4172/2161-0460.1000320
Copyright: © 2017 Yang LZ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Spinal Cord Injury (SCI) is a complex process which leads to destruction of neuronal tissue and also vascular structure. Recent many studies have shown erythropoietin (EPO) has neuro-protective effects in acute SCI animal models. Alzheimer’s disease (AD), Parkinson’s disease (PD) and SCI belong to central nervous system diseases, a few studies also indicated that EPO may be effective for AD and PD. In this a short review article, we provide a short overview of the animal and human studies on rhEPO in SCI, AD and PD. Further clinical studies should reveal whether derivatives and variants of EPO provide any benefits over the clinical application EPO to against SCI, AD and PD in the experimental studies.